Published Medical Literature

Radical Cystectomy for Bladder Cancer: Comparison of Surgical Techniques From Sweden

Case Report: Transurethral Resection for Osteosarcoma of the Bladder

Can Oxidative Stress–Related Genes Predict Outcomes for Patients With Bladder Cancer?

Update on Managing Bladder Cancer: An Evolving Landscape

Alternatives to Radical Cystectomy for Muscle-Invasive Urothelial Carcinoma: Clinical Considerations

TRIM38/GLUT1 Axis May Promote Bladder Cancer Tumorigenesis

Adding Nintedanib to Neoadjuvant Chemotherapy for Locally Advanced Bladder Cancer

Evaluating the Risk of BK Polyomavirus Infection During Childhood and Future Bladder Cancer

Seven-Gene Signature Risk Score: Predictive of Prognosis in Bladder Cancer?

Study Finds Disproportionate Racial and Ethnic Representation in Clinical Trials for Bladder Carcinoma

Can Tumor Morphology Predict Depth of Invasion in Bladder Cancer?

Early-Phase Study of Infigratinib Supports Further Work in Metastatic Urothelial Carcinoma

Predicting Recurrence in Bladder Cancer: Focus on Immune Profiles, DNA Methylation Alterations

Alternative to Intravesical Chemotherapy Under Study in Non–Muscle-Invasive Bladder Cancer

The Impact of Neoadjuvant Immunotherapy in Muscle-Invasive Bladder Cancer

Use of Cabozantinib Plus Nivolumab After Immunotherapy in Metastatic Urothelial Carcinoma

Is There a Link Between Bladder Cancer and Human Papillomavirus?

Long Non-Coding RNA: Potential Therapeutic Target in Bladder Cancer?

Predicting Prognosis in Bladder Cancer: Focus on Unfolded Protein Response–Related Gene Signature

Use of Toripalimab in the Second-Line Setting for Advanced Urothelial Carcinoma

Newly Developed and Validated Prognostic Signature for Patients With Bladder Cancer

Effect of Smoking-Related Lung Disease on Bladder Urothelial Carcinoma Survival

Pancreaticoduodenectomy for Metastasized Bladder Cancer: Case Report

Preclinical Study of Tumor Microenvironment in Bladder Cancer Offers Clues to Causes of Chemoresistance

Five-Gene Score Model Under Study in Predicting Outcomes in Bladder Cancer

Evaluating Risk-Aligned Bladder Cancer Surveillance Practices

Metastatic Urothelial Cancer: Does Prior Treatment Hinder the Effectiveness of Pembrolizumab Therapy?

Cisplatin Versus Carboplatin: Overall Survival in Dutch Cohort Study of Metastatic Bladder Cancer

Treatment of Bladder Cancer After Platinum and PD-1/L1 Inhibitor Therapy: Real-World Outcomes

Rare Combination of Fibroepithelial Polyp and Kidney Cancer in a Patient With Bladder Cancer

Can Novel ATR Inhibitor Augment Activity of Chemotherapy in Advanced Urothelial Carcinoma?

Low-Grade Bladder Cancer: Can Mitomycin-Based Chemoablation Reduce the Need for Surgery?

Can Urothelial Bladder Carcinoma Cause Chronic Knee Problems?

Case Report: Older Woman With Metastatic Bladder Cancer Responds to Pembrolizumab

Laser Versus Electrical En Bloc Resection of Bladder Tumors

CheckMate 274: Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma

Are Lebanese and Jordanian Populations at Higher Risk for Bladder Cancer?

Enfortumab Vedotin-ejfv Under Study in Cisplatin-Ineligible Urothelial Carcinoma

Rare Case of Bladder Metastasis of Kidney Cancer: Potential Role of Genomic Analysis

Bacillus Calmette-Guérin Therapy for Bladder Cancer and Likelihood of COVID-19 Infection

Feasibility Study in Upper Tract Urothelial Cancer: Neoadjuvant Pembrolizumab Before Surgery

Impact of COVID-19 on Cystoscopic Surveillance for Non–Muscle-Invasive Bladder Cancer

Treatment Patterns and Outcomes in Muscle-Invasive Bladder Cancer

Combination Therapy for Metastatic Urothelial Bladder Carcinoma With FGFR3 Mutation: A Case Study

Identifying Bladder Cancer Subtypes by Metabolic Characteristics: Therapeutic Implications

STAG2 Immunostaining: Potential Biomarker in Predicting Bladder Cancer Outcomes?

Adjuvant Nivolumab for Patients With High-Risk Muscle-Invasive Urothelial Carcinoma

Camrelizumab Treatment in Upper Tract Urothelial Carcinoma: Case Report

Hypoxia-Related Gene Signature: An Independent Clinical Predictor in Bladder Cancer?

Mixed Results With Rucaparib in ATLAS Trial in Metastatic Urothelial Cancer

CALGB 90601: Combination Gemcitabine and Cisplatin With Bevacizumab in Urothelial Carcinoma

Resistant Urothelial Carcinoma: Organ-Specific Response to Pembrolizumab

The Hormone Ghrelin: Potential Prognostic Predictor in Muscle-Invasive Bladder Cancer?

Rare Complication of Intravesical BCG Therapy for Bladder Cancer: Case Report

Is Dietary Acrylamide Intake Associated With the Development of Bladder Cancer?

Does a Family History of Any Cancer Increase the Risk for Bladder Cancer?

Do Men and Women With Urinary Bladder Cancer Respond Differently to BCG Immunotherapy?

Can Treatment-Specific COXEN Scores Predict Responses to Neoadjuvant Chemotherapy for Bladder Cancer?

Diagnostic Utility of Serum N‐glycan Profiles in Urothelial Carcinomas

TP53-Mutated Bladder Cancer: Identifying Patients Who May Benefit From Immunotherapy

Does Use of Aspirin Improve Outcomes in Older Adults With Bladder Cancer?

Prescription of Psychotropic Drugs in Older Patients With Bladder Cancer

Low-Dose BCG Tokyo Strain for Non–Muscle-Invasive Bladder Cancer

Unleashing the Therapeutic Potential of Natural Compounds Against Bladder Cancer

Systemic Treatment of Metastatic Bladder Cancer: Dutch Study of Current Clinical Practice

Radical Cystectomy Versus BCG Treatment for High-Risk Bladder Cancer

Novel Prognostic Biomarker for Bladder Cancer Investigated

Immunotherapy for Urothelial Cancer: Balancing Benefits and Risks

Preferred Treatment for Invasive Bladder Cancer: Intravesical Immunotherapy or Radical Cystectomy?

Measures of Tumor Heterogeneity: Useful Biomarkers of Bladder Carcinoma?

Study Identifies Potential Biomarker of Bladder Carcinoma Recurrence

Impact of Preoperative Positive Voided Urine Cytology on Prognosis in Urothelial Cancer

Intravesical Nadofaragene Firadenovec in Non–Muscle Invasive Bladder Cancer

Ramucirumab Plus Docetaxel in Urothelial Carcinoma: Patient-Reported Outcomes From RANGE Trial

Pelvic Radiotherapy Combined With Chemotherapy in Metastatic Urothelial Cancer

Predicting Risk of Recurrence in Nonmuscle‐Invasive Bladder Cancer

Preoperative Chemotherapy for High-Grade Upper Tract Urothelial Carcinoma

Nab-paclitaxel Versus Paclitaxel in Metastatic Urothelial Cancer

Surveillance Strategy for Patients With Upper Tract Urothelial Carcinoma

Dose-Dense Chemotherapy for Muscle-Invasive Bladder Cancer: Phase III Trial Toxicity Update

Case Study: Neoadjuvant Pembrolizumab in Chemoresistant Urothelial Carcinoma

Targeting Bladder Carcinoma in Situ With Novel Gene Therapy

After Surgery for Upper Urinary Tract Urothelial Carcinoma: Surveillance or Chemotherapy?

Potential Genomic Predictors of Outcomes in High-Grade T1 Bladder Cancer

DANUBE Trial: Survival Outcomes With Durvalumab in Advanced Urothelial Carcinoma

Combination Regimen Under Study in Metastatic Urothelial Carcinoma

Update on Managing Non–Muscle-Invasive Bladder Cancer

Can Leukocyte Telomere Length Predict Bladder Cancer Risk?

Bladder Urothelial Carcinoma: Is Age Related to Risk of Lymph Node Metastasis?

Early Results With Buparlisib in Treatment of Metastatic Urothelial Carcinoma

Testicular Tuberculosis: Case Study of Rare Complication of Urothelial Cancer Treatment

Perioperative Chemotherapy for High‐Risk Upper Tract Urothelial Carcinoma

Early Findings With Magnetic Resonance–Guided Radiotherapy for Bladder Cancer